Biotech of the Week: MolMed, Immuno-oncology made in ‘Milano’

April 1, 2016 - 1 minute

From one fashion capital to the other, this week we leave Paris and head down to Milan. Home to some worldwide high-fashion brands, Da Vinci’s Last Supper mural and main city of the Lombardy region, Milan is also where MolMed, our Biotech of the Week, is based.


City: Milan (Italy)

Founded: 1996

Employees: (+/-) 120 (as of 12/2015)

Financial Data: €13.52M Revenues (in 2015)

CEO: Riccardo Palmisano

Content continues below

Related Content

Ricardo_Palmisano_CEO_Molmed

 

Mission: MolMed is active in the development, research and clinical validation of novel antitumour therapies. On their pipeline you have two major novel therapeutics in current clinical development: TK, a ex vivo cell therapy, enabling safe HSCT from partially compatible haplo-identical donors (e.g close relatives i.e mother, father, brothers or sisters), who are available for most of all patients and NGR-hTNF, a novel vascular targeting agent, in Phase II in four different indications: colorectal, small-cell lung and liver cancers, and malignant pleural mesothelioma.

Led by current CEO Riccardo Palmisano since December 2015, MolMed is also listed on the Milan stock exchange (market cap +-€150M).

Comment: MolMed is one of the biggest Biotech company in Italy, and their achievements make them a reliable and well-founded choice for our Biotech of the Week.

You might also be interested in the following: